Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 19, 2017 | September 21, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date September 19, 2017 · Filed September 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,000 |
Reported balance
After 2017-09-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-09-19 · Grant · Acquired 9,000 · Balance 82,000 F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This restricted stock unit award vests in full, one year following September 19, 2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $21.75 · Expires 2025-09-18 | Direct | 22,500 |
Reported balance
After 2017-09-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-09-19 · Grant · Acquired 22,500 · Balance 22,500 F3: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This restricted stock unit award vests in full, one year following September 19, 2017.
F3: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2017 Filed Sep 21, 2017 20:46 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-17-053615 · doc4.xml · derivative · entry 2 Krivulka Joseph J · CIK 0001296750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: common stock · 22,500 shares Expires 2025-09-18 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:46 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053615 · doc4.xml · nonDerivative · entry 1 Krivulka Joseph J · CIK 0001296750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 19, 2017. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 22:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0001209191-17-042168 · doc4.xml · derivative · entry 2 Krivulka Joseph J · CIK 0001296750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 22:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $8.37 | $125,550.00 |
DisclosureSEC source: 0001209191-17-042168 · doc4.xml · nonDerivative · entry 1 Krivulka Joseph J · CIK 0001296750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:11 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001209191-16-142666 · doc4.xml · derivative · entry 2 Krivulka Joseph J · CIK 0001296750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-09-20 F3 · derivative.exercise_date: This option vests in equal monthly installments over the one-year period beginning on September 30, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:11 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142666 · doc4.xml · nonDerivative · entry 1 Krivulka Joseph J · CIK 0001296750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 21, 2016. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142025 · doc4.xml · derivative · entry 2 Krivulka Joseph J · CIK 0001296750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F1 · derivative.exercise_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F1 · derivative.expiration_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142025 · doc4.xml · nonDerivative · entry 1 Krivulka Joseph J · CIK 0001296750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F2 · balance_after: The total holdings includes the 15,000 shares of restricted stock units ("RSUs") that were previously reported in Table II for the reporting person and which are being reclassified to Table I. These RSUs were granted on September 15, 2015, are convertible on a one-for-one basis into shares of Common Stock of the Company, and vested on September 15, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.